GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2(+)/HER2(-) advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ) Meeting Abstract


Authors: Xu, R. H.; Ajani, J. A.; Al-Batran, S. E.; Bang, Y. J.; Catenacci, D.; Enzinger, P. C.; Ilson, D. H.; Kim, S.; Lordick, F.; Shitara, K.; van Cutsem, E.; Arozullah, A.; Park, J. W.; Shah, M. A.
Abstract Title: GLOW: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin18.2(+)/HER2(-) advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)
Meeting Title: ESMO Asia Virtual Congress 2020
Journal Title: Annals of Oncology
Volume: 31
Issue: Suppl. 6
Meeting Dates: 2020 Nov 20-22
Meeting Location: Virtual
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2020-11-01
Start Page: S1315
End Page: S1316
Language: English
ACCESSION: WOS:000600988900197
DOI: 10.1016/j.annonc.2020.10.459
PROVIDER: wos
Notes: Meeting Abstract: 195TiP -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. David H Ilson
    435 Ilson